Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon, BehaVR Seal Deal on VR Digital Therapeutics
October 20, 2021
- Chugai, Oncolys to Call Off License Deal for Telomelysin
October 20, 2021
- Japan Joins Global PIII Schizophrenia Program for GlyT1 Inhibitor: BI
October 20, 2021
- Veklury Now Available in Normal Distribution Channel in Japan
October 19, 2021
- Lenvima/Keytruda Gets European Panel Nod for RCC, Endometrial Carcinoma
October 19, 2021
- JCR’s Hunter Syndrome Drug Earns PRIME Tag in Europe
October 19, 2021
- Alfresa to Introduce Digital-Driven Deliveries at All Offices by August 2024; Test Run Showing Good Results
October 18, 2021
- Pfizer Japan, Health Tech Startup Join Hands in AI-Powered Support for OAB Patients
October 18, 2021
- Pfizer/Mylan/Viatris to Discontinue 18 Generic Drugs
October 15, 2021
- Shionogi President Urges Govt to Stockpile Infectious Disease Drugs
October 14, 2021
- MSD, Maruho Warn of Ivermectin Prescribing for COVID-19, Stressing Such Use Not Approved
October 14, 2021
- Abraxane Supply to Continue until Mid-December without Possible Stockouts: Taiho
October 13, 2021
- Japan Drug Makers Prepping to Launch New Organization to Solve Challenges in Digital Health
October 13, 2021
- Lack of Management Response, Tight Manufacturing Plans to Blame in Choseido Issue: Report
October 12, 2021
- Chugai Seeks Japan Nod for Ronapreve in Prophylaxis, Asymptomatic COVID-19
October 12, 2021
- Sales Reps’ Detailing Activities Decrease by 3.4% in August: Intage
October 12, 2021
- Ivermectin COVID-19 Trial Needed Because Evidence Is Lacking, Kowa Says as It Aims for PIII Wrap-Up in November
October 11, 2021
- Takeda’s CMV Drug Maribavir Earns FDA AdCom Backing
October 11, 2021
- Licensing Izcargo to Takeda First Step to Expanded Application of JCR’s BBB-Penetrating Technology: Chairman
October 8, 2021
- Kyowa Kirin Calls Off Entinostat Breast Cancer Program in Japan
October 8, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…